Survival Rate Changes in Neonates with Congenital Diaphragmatic Hernia and its Contributing Factors by Kim, Do-Hyun et al.
INTRODUCTION
Congenital diaphragmatic hernia (CDH) occurs in 1 per
2,000-5,000 live births and affects approximately 1,100
infants annually in the U.S.A. (1). CDH remains one of the
most challenging and perplexing malformations in neonatal
intensive care units (NICUs), and shows a high mortality
rate due to pulmonary hypoplasia and/or intractable persis-
tent pulmonary hypertension (PPH), despite aggressive peri-
natal treatment. However, the relative rarity and clinical vari-
ability of CDH makes it difficult to conduct well-designed
clinical studies at a single institution and to establish the most
suitable treatment. Despite advances in neonatal intensive
care over the last 2 decades, the overall survival rate of neonates
with CDH (64%) has changed only slightly in recent years,
and to date, uniform standards for CDH management have
not been established (2-4). 
Advanced therapies for CDH have included delayed oper-
ation, extracorporeal membrane oxygenation (ECMO), high-
frequency oscillatory ventilation (HFOV), surfactant, and
inhaled nitric oxide (iNO) therapy. However, the effects of
these modalities in terms of statistically significant survival
advantage in neonates with CDH have not been clearly deter-
mined. In particular, the effect of iNO on the outcome in
CDH remains controversial (5-7). 
In June 1998, iNO therapy was introduced as a new treat-
ment modality in the NICU at Seoul National University
Children’s Hospital. Following the introduction of this the-
rapy, we found that the survival rate of neonates with CDH
had changed, and thus, we conducted this retrospective study
to determine whether iNO therapy had influenced the sur-
vival rate, or whether the initial clinical characteristics of
patients had co-incidentally become less severe. Thus, the
purpose of this study was to determine survival rate changes
after the introduction of iNO therapy, and to identify the
factors that influence these changes in neonates with CDH
at our institution.
MATERIALS AND METHODS
Study patients
The medical records of 55 CDH patients, admitted to Seoul
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Survival Rate Changes in Neonates with Congenital Diaphragmatic
Hernia and its Contributing Factors
The purpose of this study was to demonstrate survival rate changes after the intro-
duction of inhaled nitric oxide (iNO) therapy, and to identify the factors that influence
these changes in neonates with a congenital diaphragmatic hernia (CDH) at a sin-
gle center. A total of 48 neonates were divided into two groups based on the time
of admission, i.e., into period I (P1; n=17; before the introduction of iNO therapy)
and period II (P2; n=31; after the introduction of iNO therapy). Survival rates of the
48 neonates showed a tendency to increase from 53% during P1 to 77% during
P2, but without a statistical significance, but a significant difference was found bet-
ween survival rates during the two periods after adjusting for initial clinical charac-
teristics, when the postoperative survival rate increased significantly from 69% for
P1 to 100% for P2. The mean duration of preoperative respiratory management
was significantly longer for P2 than for P1. Seven of 12 patients who received pre-
operative iNO therapy due to persistent pulmonary hypertension or refractory pre-
ductal hypoxemia in P2 survived after operation. We speculate that a management
strategy based on iNO therapy and delayed operation, rather than differences bet-
ween the initial clinical characteristics of the two study groups, might partially con-
tribute to the observed improvements in postoperative and overall survival rates in
neonates with CDH.
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National University Children’s Hospital between 1 January
1990 and 31 May 2005, were reviewed retrospectively. Four
infants who were admitted after the neonatal period, two
neonates with chromosomal abnormalities or multiple mal-
formations, and one neonate who succumbed to septic shock
were excluded. A total of 48 neonates were included in this
study and were divided into two groups according to the
time point of admission, i.e., prior to or after the introduc-
tion of iNO therapy. Seventeen neonates were admitted dur-
ing the period I (P1; January 1990 to May 1998; before the
introduction of iNO therapy), and 31 neonates during the
period II (P2; June 1998 to May 2005; after the introduc-
tion of iNO therapy). Data on patients’ clinical characteris-
tics and outcomes were collected and analyzed retrospectively.
A flow diagram showing the course and outcome of all CDH
patients enrolled in this study is presented in Fig. 1. The study
was approved by the institutional research ethics committee.
Respiratory management
To treat neonates with CDH showing respiratory distress,
a conventional ventilator (CV) was generally started as the
primary ventilation mode for inborn patients or on admis-
sion for outborn patients as follows; mean airway pressure
(MAP), 5-10 mmHg; fraction of inspired O2 (FiO2), 0.4-1.0;
and frequency, 40-60/min. If preoperative stabilization was
not achieved using a CV (pH <7.25, PaCO2 >65 mmHg,
and PaO2 <50 mmHg at MAP ≥10 mmHg, frequency ≥
60/min, and FiO2 ≥0.6), HFOV was applied. Initial HFOV
settings were as follows: FiO2, 0.6-1.0; frequency, 15 Hz;
stroke volume, 10-15 mL; MAP, 2-3 cmH2O above the CV
setting. In some patients, depending on the clinical state,
HFOV was started as the primary ventilation mode. At our
institution, an iNO delivery system (Metran Massmixer, Me-
tran Co., Kawaguchi, Japan) and a high-frequency oscillato-
ry ventilator (Humming V, Metran Co., Kawaguchi, Japan)
were first introduced in June 1998 and in August 1996,
respectively. During P2, iNO was administered in addition
to HFOV when PPH (right-to-left shunt on echocardiogram,
difference between preductal and postductal saturation of
oxygen >10%) or refractory preductal hypoxemia (pH <7.25,
PaO2 <50 mmHg, and SaO2 <85% at MAP ≥15 mmHg
and FiO2 ≥0.6) developed despite HFOV. The concentra-
tion of iNO was initiated at 5-20 ppm and increased to a
maximum of 80 ppm. Reduction of the oxygenation index
(OI=[MAP×FiO2×100]/PaO2) to 30% or more within 24
hr was defined as a clinical response, and a reduction of OI
to under 30% or increase of OI within 24 hr was defined as
a clinical no-response (8). Respiratory management data were
collected and analyzed. During P1 and P2, a CDH repair
operation was performed when clinical conditions had been
stabilized to some degree (pH ≥7.25, OI <12, and stable
vital signs). The operation was not performed when clinical
conditions had not stabilized (pH <7.25, OI ≥12, and un-
stable vital signs). Postoperative respiratory management
was performed as described for the preoperative protocol. 
Statistics
Data were presented as means±standard deviations. Con-
tinuous variables were compared using the Mann-Whitney
U test. Categorical variables were compared using the chi-
square and Fishers exact tests. p values of less than 0.05 were
considered significant. Survival analysis was based on 7 days
of survival data. Survival curves were constructed using the
Kaplan-Meier method. Cox regression analysis was used to
determine whether the survival rates of the periods were dif-
ferent and independent of initial clinical characteristics. Sta-
tistical analysis was performed using SPSS version 12.0.
Enrolled patients
(n=55)
Exclusion criteria
1. Admission to NICU after neonatal period (n=4)
2. Chromosomal abnormality (n=1)
3. Multiple malformations (n=1)
4. Cause of death: septic shock (n=1)
Study patients
(n=48)
Period I
(n=17)
Operation
(n=13)
Operation
(n=24)
No-operation
(n=4)
No-operation
(n=7)
Period II
(n=31)
Survival
(n=9)
Death
(n=4)
Death
(n=4)
Survival
(n=24)
Death
(n=7)
Fig. 1. Flow diagram showing the courses and outcomes of the 55 patients with congenital diaphragmatic hernia (CDH) enrolled in this study.
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RESULTS
Clinical characteristics 
Clinical characteristics of the patients enrolled during the
two periods are given in Table 1. The rates of inborn delivery
and prenatal diagnosis were significantly higher during P2
than during P1. No significant differences were observed
between the two periods in terms of any other clinical char-
acteristics.
Change in survival rate 
The overall survival rate of the 48 CDH patients was 69%
(33 of 48), and the survival rate increased from 53% (9 of
17) during P1 to 77% (24 of 31) during P2 (Table 1). All
deaths (15 patients) occurred before six days of life (2-146 hr),
and eight patients died before 24 hr of life. All deaths occurred
as a result of PPH or refractory hypoxemia. When survival
rates over the first 7 days after birth were analyzed using Ka-
plan-Meier curves for the two periods (not shown), the sur-
vival rate for P2 was higher than that for P1, but without a
significant difference (p=0.096). However, after adjusting for
the initial clinical characteristics (sex, gestational age, birth
weight, Apgar score at 5 min, significant associated anoma-
lies, prenatal diagnosis, inborn delivery, polyhydramnios, and
liver herniation), this difference between the two periods
achieved a significance (p=0.033) (Table 2). Thirty-seven of
the 48 patients (P1, 13 of 17; P2, 24 of 31) underwent an
operation (Table 3). Postoperative survival rates increased
*p=0.032 vs. Period I; 
� p=0.001 vs. Period I; 
� Associated anomalies ex-
cluding patent ductus arteriosus and atrial septal defect.
PPHN, persistent pulmonary hypertension of the newborn; CDH, con-
genital diaphragmatic hernia.
Period I 
(n=17)
Period II
(n=31)
Total
(n=48)
General characteristics
Inborn, n (%) 7 (41) 23 (74)* 30 (63)
Male gender, n (%) 9 (53) 24 (77) 33 (69)
Birth weight (kg) (range) 2.94±0.73 3.09±0.56 3.03±0.62 
(1.3-4) (1.9-4.1) (1.3-4.1)
Gestation age (wk) (range) 38.5±3.1 38.7±1.8 38.7±2.3
(29-42) (34-42) (29-42)
Vaginal delivery, n (%) 9 (53) 17 (55) 26 (54)
Apgar score (5-min) (range) 6.2±2.1 6.7±1.8 6.9±1.6
(1-9) (2-9) (1-9)
CDH characteristics
Prenatal diagnosis, n (%) 4 (24) 23 (74)
� 27 (56)
Polyhydramnios, n (%) 3 (18) 9 (29) 12 (25)
Significant associated  4 (35) 4 (68) 8 (17)
anomalies
� , n (%)
Side of defect, n (%)
Right 2 (12) 5 (16) 7 (15)
Left 15 (88) 23 (74) 38 (79)
Bilateral or central 0 (0) 3 (10) 3 (6)
Herniation of liver, n (%) 4 (24) 8 (26) 12 (25)
Associated pneumothorax, n (%) 2 (12) 5 (16) 7 (15)
Documented PPHN, n (%) 4 (24) 9 (29) 13 (27)
Onset of respiratory distress, n (%)
Early (≤24 hr) 15 29 44 (92)
Late (>24 hr) 2 2 4 (8)
Survivors, n (%) 9 (53) 24 (77) 33 (69)
Table 1. Clinical characteristics and survival rates during peri-
ods I and II
*Sex, gestational age, birth weight, Apgar score at 5 min, significant
associated anomalies, prenatal diagnosis, inborn delivery, polyhydram-
nios, and liver herniation.
CI, confidence interval.
Hazard ratio 95% CI p value
Period I 1
Period II 0.135 0.021-0.846 0.033
Table 2. Changes in survival rates between periods I and II after
adjusting for the initial clinical characteristics* (by Cox regres-
sion analysis)
*p=0.011 vs. Period I; 
� p=0.041 vs. Period I; 
� p=0.001 vs. Period I.
HFOV, high-frequency oscillatory membrane oxygenation; PIP, peak inspiratory pressure; MAP, mean airway pressure; FiO2, fraction of inspired O2.
Period I (n=13) Period II (n=24)
Survivors after operation, n (%) 9 (69%) 24 (100%)*
Preoperative iNO therapy, n (%)  - 7 (30)
Duration (hr) (range) - 31±28.1 (4-96)
Postoperative iNO therapy, n (%) - 6 (25)
Duration (hr) (range) - 193±130 (16-408)
Preoperative HFOV therapy, n (%) 4 (31) 12 (50)
Duration (hr) (range) 18.5±16.6 (6-43) 34.4±26.4 (8-96)
Profiles of preoperative respiratory care  
Duration of intubation (hr) (range) 23.4±15.4 (2-47) 39.5±22.9 (10-96)
�
Duration of ventilator care (hr) (range) 15.1±12.9 (2-47) 38.7±23.3 (10-96)
�
PIP (max. cmH2O) (range) 20.3±5 (14-26) 19.1±3.8 (13-25)
MAP (max. cmH2O) (range) 9.86±4 (4-17) 9.87±3.1 (6-20)
FiO2 (max.) (range) 0.74±0.28 (0.4-1) 0.61±0.2 (0.4-1)
Table 3. Pre- and postoperative respiratory management of patients who underwent operation690 D.-H. Kim, J.D. Park, H.-S. Kim, et al.
significantly from 69% (9 of 13) in P1 to 100% (24 of 24)
in P2. 
Pre- and postoperative respiratory management 
Pre- and postoperative respiratory managements during
the two periods are summarized in Table 3. The number of
patients who received HFOV therapy before operation was
not significantly different between the two periods. Howev-
er, the mean durations of preoperative intubation and mecha-
nical ventilation were significantly longer in P2 than in P1,
and the mean duration of preoperative mechanical ventila-
tion in survivors was also significantly longer in P2 than in
P1 (data not shown, 13.1±7.9 hr vs. 40.6±24.3 hr, p=
0.003). Mean maximal preoperative peak inspiratory pres-
sure (PIP), MAP, and FiO2 were not significantly different
in P1 and P2. Mean maximal preoperative PIP, MAP, and
FiO2 in P2 were measured before iNO therapy.
Outcome of patients who received iNO therapy during
period II 
Twelve of 31 patients in P2 received iNO therapy (Fig. 2).
Initial OI was above 12 in all patients who received iNO
therapy (data not shown). Seven of the 12 were regarded as
clinical responders and five as non-responders. Six of the seven
patients in the clinical response group underwent operation,
and five of the six patients survived after postoperative iNO
therapy, and one patient survived without postoperative iNO.
Only one of the five patients in the clinical no-response group
underwent operation, and survived after postoperative iNO
therapy. This patient had the lowest initial OI (=12) in the
clinical no-response group. In total, 7 of 12 patients who
received iNO therapy in P2 survived postoperatively. 
DISCUSSION
Comparisons of survival rates of CDH patients between
institutions or periods are difficult and controversial because
the spectrum of disease severity is very wide. In recent retro-
spective reviews of CDH cases in the United Kingdom (a
13-yr study) and France (a 5-yr study), overall survival rates
ranging between 50% and 56% were observed (9, 10). More
recently, the Congenital Diaphragmatic Hernia Study Group
reported an overall survival rate of 64% based on data from
71 institutions in North America, Europe, and Australia
(4). Thus, the overall survival rate of 69% at our institution
(a 15-yr study) is similar to or higher than those reported
from other institutions (2, 4, 9-11). However, the survival
rate of 69% at our institution has not been constant over
the 15-yr period. After iNO therapy was introduced in June
1998, we noticed a change in the survival rates of neonates
with CDH. Thus, to investigate this change in survival rate,
we divided the study cohort into two groups according to
the admission date, i.e., prior to (P1) or after (P2) the intro-
duction of iNO therapy. Increases in inborn delivery and
prenatal diagnosis in P2 can be explained by the fact that
prenatal diagnosis has gradually become routine with the
advent of frequent screening ultrasonography during preg-
nancy, and thus, more mothers with a prenatal diagnosis of
CDH are referred to a tertiary-care center equipped with
‘immediate planned care’.
No significant difference was observed between the survival
Period II
(n=31)
iNO
(n=12)
Responders
(n=7)
Non-responders
(n=5)
Operation
(n=6)
No-operation
(n=1)
Operation
(n=1)
No-operation
(n=4)
Operation
(n=17)
No-operation
(n=2)
No iNO
(n=19)
Survival
(n=6)
Death
(n=1)
Death
(n=4)
Survival
(n=17)
Death
(n=2)
Survival
(n=1)
iNO (n=5)
iNO (n=1)
Fig. 2. Outcomes of pre- and postoperative iNO therapy for neonates with congenital diaphragmatic hernia during period II.rates of the two periods by Kaplan-Meier curve analysis, des-
pite the fact that the survival rate obtained after the intro-
duction of iNO therapy was higher than during the previ-
ous period. Thus, additional evaluation was necessary because
ranges of severity and clinical variability in CDH at the time
of birth made it difficult to simply compare the survival rates
of the two periods. Therefore, we compared period survival
rates after adjusting for initial clinical characteristics related
to the survival rate, i.e., sex, gestational age, birth weight
(4), Apgar score at 5 min (4), significant associated anoma-
lies (7, 12-14), prenatal diagnosis, inborn delivery (12, 15),
polyhydramnios (16), and liver herniation (17). Among the
above initial clinical characteristics, birth weight and Apgar
score at 5 min were found to be the most important predic-
tors to estimate the severity of CDH in the first 5 min of life
by the Congenital Diaphragmatic Hernia Study Group (4).
The lung-to-head ratio (18), one of the reliable predictors to
help determine postnatal survival in CDH, was excluded
from survival analysis because the rate of outborn delivery
without prenatal diagnosis was very high at our institution.
However, we considered that the significance of the lung-
to-head ratio could be reflected to some degree by initial clin-
ical characteristics such as Apgar score at 5 min. We also
excluded clinical characteristics such as pneumothorax caused
by CDH management from survival analysis. According to
this analysis, the survival rate of P2 was significantly higher
than that of P1. This result suggests that the survival rate
difference observed between the two periods is likely to have
been influenced by the change of management strategy rather
than due to differences between the above initial clinical
characteristics, including prenatal diagnosis and inborn deliv-
ery, which were significantly different between P1 and P2.
The significant differences in the management strategy
between the two periods in this study were the introduction
of iNO therapy and the longer duration of preoperative res-
piratory management in P2. Preoperative HFOV therapy
was excluded from evaluation of further management strat-
egy because the number of patients who received HFOV
therapy preoperatively was not significantly different between
the two periods. The most important aspect of the postnatal
management of neonates with CDH is PPH management
(7). NO, originally identified as endothelial derived relaxing
factor, has been used successfully to treat PPH because it is
a potent vasodilator (19). Some investigators have tried iNO
therapy in neonates with PPH complicating the course of
CDH (20, 21). However, a multicenter randomized controll-
ed trial of iNO therapy in CDH patients failed to demon-
strate any reduction in the need for ECMO or in mortality
(5). These results are consistent with previous observations
by another group, who found that early iNO therapy was
not associated with significant improvements in oxygena-
tion in neonates with CDH (22). On the other hand, other
studies favor the effect of iNO therapy in neonates with CDH,
although these were not controlled studies (15, 23). Recent-
ly, Downard et al. suggested that iNO therapy could be an
important adjunct for treating PPH in neonates with CDH,
when used in concert with echo- cardiography (7). The results
of our study seem to support those of previous studies, which
found that iNO therapy is effective in the management of
CDH. In the present study, the postoperative survival rate
in the P2 group was significantly higher. Among the 12 pa-
tients who received iNO therapy as a rescue therapy for PPH
and refractory hypoxemia in P2, seven patients survived post-
operatively. It is possible that the survival of these seven pa-
tients in P2 was partly attribu- table to the introduction of
iNO therapy. We mentioned above that a reduction in the
oxygenation index to 30% or more within 24 hr of iNO ther-
apy was defined as a clinical response (8). This definition is
meaningful in that most of the clinical responders (6 of 7)
in P2 survived after operation, and thus contributed to im-
proved survival in P2. Another significant difference in man-
agement strategies in this study was the longer duration of
preoperative respiratory management in P2. Several resear-
chers have suggested that delayed operation for CDH after
prolonged stabilization for at least 24 hr has a beneficial
effect on survival rate for patients with CDH (2, 7, 24). In
our study, we believe that iNO therapy is one of the factors
that made delayed operation possible in P2, although more
severe preoperative respiratory conditions may have been
responsible for these delays.
Some recent studies similar to our own allow comparisons
of the survival rates of neonates with CDH with historical
controls (23, 25-27). Three of these studies reported dramati-
cally improved survival rates in neonates with CDH during
1988-2000, 1978-2001, and 1996-2001, respectively (23,
26, 27). However, only Okazaki et al. reported that the sur-
vival rate of neonates with CDH was improved significantly
after the introduction of iNO therapy with a delayed opera-
tion (26). One of the most important limitations of the above
studies, including the present study, concerns the use of a
historical control, which may mislead investigators believe
that changes in survival rate over a period is the direct result
of a new therapy. All of the above studies did not prove statis-
tically that the improved survival rate observed in the later
period was not related to a less severe clinical condition. As
mentioned above, the spectrum of severity of CDH is very
wide, and the determination of effects of some specified treat-
ment for this disease is very difficult. In this study, we tried
to adjust for some initial clinical characteristics that might
have influenced survival rates mainly, and to minimize con-
founding features of a study using a historical control. How-
ever, present study also has some limitations to adjust for all
initial clinical characteristics due to its retrospective nature
as other previous studies. Further prospective studies will be
required to overcome these limitations and to confirm our
hypothesis raised in this study.
In summary, a significant improvement in the survival rate
of neonates with CDH after the introduction of iNO thera-
Comparison of Pre- and Post-inhaled Nitric Oxide (iNO) Therapy 691py was observed after adjusting for initial clinical character-
istics. The improved survival of neonates with CDH seems
to be associated with an improved postoperative survival rate
after the introduction of iNO therapy. We speculate that a
management strategy based on iNO therapy and delayed
operation, rather than differences between the initial clini-
cal characteristics of the two study groups, might have par-
tially contributed to the improvements observed in postop-
erative and overall survival rates in neonates with CDH.
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